This article addresses what I consider the most important safety disclosure in the pentosan polysulfate space. If you use PPS for any indication — interstitial cystitis, osteoarthritis, or anything else — you need to understand this risk.
Pentosan polysulfate maculopathy is a recently identified, dose-dependent, progressive, and currently irreversible retinal toxicity associated with long-term PPS use. It was first described in 2018, decades after PPS was approved by the FDA for interstitial cystitis in 1996. This means that thousands of patients used PPS for years without anyone knowing this risk existed.
Here is what the evidence shows.
At a Glance
| Property | Value |
|---|---|
| First Described | 2018 (Pearce et al., Ophthalmology) |
| FDA Labeling Update | 2020 |
| Risk Factor | Cumulative exposure (total grams of PPS ingested) |
| Typical Exposure for Risk | 3+ years of oral PPS at 300 mg/day |
| Prevalence Estimate | 16-24% of long-term oral PPS users show subclinical findings |
| Symptoms | Difficulty reading, paracentral scotomas, prolonged dark adaptation |
| Pathology | Retinal pigment epithelium (RPE) damage, pigment migration in macula |
| Reversibility | Not reversible; may progress after discontinuation |
| Screening Method | OCT, fundus autofluorescence, near-infrared reflectance |
The Discovery: A Toxicity Hidden for 22 Years
PPS (Elmiron) was approved by the FDA in 1996 for interstitial cystitis (IC), a chronic bladder condition. For over two decades, it was considered to have a benign side effect profile. Then in 2018, Nieraj Jain and William Pearce at Emory University published a landmark paper describing a novel macular disease in patients with long-term PPS exposure.
Their observation was striking: a pattern of retinal pigmentary changes in the macula that did not match any known macular dystrophy. The pattern was unique — dense, pigmented deposits in the parafoveal region with RPE atrophy — and it was found exclusively in patients taking PPS.
The significance of this discovery cannot be overstated. PPS was prescribed to hundreds of thousands of patients for IC over two decades, and the retinal toxicity was either missed or misdiagnosed as age-related macular degeneration. The pattern was only identified when an ophthalmologist happened to notice the same unusual retinal appearance in multiple patients who shared one common medication.
What PPS Maculopathy Looks Like
The Clinical Presentation
Patients with PPS maculopathy present with a constellation of visual symptoms that develop insidiously:
- Difficulty reading. The earliest and most common complaint. Small print becomes progressively harder to read, even with corrective lenses.
- Paracentral scotomas. Small blind spots or dim areas near the center of vision. Patients may describe a dark spot just to the side of where they are looking.
- Prolonged dark adaptation. Difficulty adjusting to dim lighting. Driving at night becomes more difficult.
- Metamorphopsia. Distortion of straight lines (similar to wet macular degeneration).
- Reduced contrast sensitivity. Images appear washed out or less vivid.
The insidious onset is a key concern. Symptoms develop gradually over months to years, and patients may attribute them to normal aging or changes in their glasses prescription. By the time symptoms are recognized as PPS-related, significant structural damage may already be present.
The Imaging Findings
Modern retinal imaging reveals characteristic abnormalities:
Fundus autofluorescence (FAF): A distinctive pattern of dense, hyperautofluorescent spots surrounded by a halo of hypoautofluorescence in the macula. This pattern is sufficiently unique that experienced ophthalmologists can identify PPS maculopathy from FAF alone.
Optical coherence tomography (OCT): Disruption of the outer retinal layers, particularly the RPE and photoreceptor-RPE junction. Focal areas of RPE thickening and thinning are visible, along with subretinal deposits.
Near-infrared reflectance (NIR): Dense, dark perifoveal spots that correspond to the areas of RPE disruption.
Fluorescein angiography: Window defects corresponding to RPE atrophy, with characteristic “leopard spotting” pattern.
The Risk Factors: Dose and Duration
Cumulative Exposure Is the Key Variable
The risk of PPS maculopathy correlates primarily with cumulative exposure — the total amount of PPS ingested over time. This is expressed as total grams consumed or, more practically, as daily dose multiplied by duration of use.
The numbers from published screening studies:
- Pearce et al. (2018): Identified 6 patients with characteristic maculopathy, all with exposure exceeding 3 years at standard doses
- Jain et al. (2019): Screened 219 PPS-exposed patients and found subclinical retinal changes (detectable on imaging but not yet symptomatic) in approximately 16% of those with exposure exceeding 500 grams total
- Hanif et al. (2019): Found retinal abnormalities in 24% of patients with a mean PPS exposure of 186,000 mg (186 grams total) and a mean duration of 15 years
The Standard IC Exposure
The FDA-approved dose for interstitial cystitis is 100 mg orally, three times daily (300 mg/day). At this dose:
| Duration | Cumulative Exposure | Estimated Risk |
|---|---|---|
| 1 year | ~110 grams | Very low |
| 3 years | ~330 grams | Low-moderate (screening recommended) |
| 5 years | ~548 grams | Moderate (subclinical changes common) |
| 10 years | ~1,095 grams | Significant |
| 15+ years | ~1,643+ grams | High (approximately 1 in 4 show changes) |
What About Subcutaneous PPS for Osteoarthritis?
This is the question my OA patients ask, and the answer provides important context:
A typical subcutaneous PPS course for knee osteoarthritis involves:
- 150 mg per injection (for a 75 kg patient)
- 12 injections over 8 weeks
- Total per course: approximately 1.8 grams
- Annual exposure (with 2 courses/year): approximately 3.6 grams
Compare this to IC use: 300 mg/day x 365 days = approximately 110 grams per year.
The annual exposure difference is approximately 30-fold. OA patients receive roughly 3-4 grams per year. IC patients receive roughly 110 grams per year.
No published cases of PPS maculopathy have been reported from subcutaneous OA protocols. The risk is theoretically much lower due to:
- Dramatically lower cumulative exposure
- Intermittent rather than continuous administration
- Subcutaneous bioavailability may differ from oral absorption
However, the absence of reported cases is not the same as the absence of risk. For patients planning repeated courses over years, ophthalmological monitoring is still prudent.
The Irreversibility Problem
The most concerning aspect of PPS maculopathy is that it appears to be irreversible and can progress even after PPS is discontinued.
Post-discontinuation progression: Multiple case reports document patients whose retinal findings worsened over months to years after stopping PPS. This suggests that the drug or its metabolites accumulate in retinal tissue and continue to exert toxic effects after systemic exposure ends.
No treatment available. Unlike wet macular degeneration (which can be treated with anti-VEGF injections) or diabetic maculopathy (which responds to laser and medication), PPS maculopathy has no proven treatment. The RPE damage is structural, and current medicine cannot regenerate damaged RPE cells.
Early detection matters most. Because the condition is irreversible, the greatest clinical value is in early detection — identifying subclinical changes before vision loss occurs, so that PPS can be discontinued before symptomatic damage develops.
Screening Recommendations
Who Should Be Screened
Based on current evidence and expert consensus:
- All patients on oral PPS for IC — regardless of duration, but with particular urgency for those with 3+ years of use
- Any PPS user with new visual symptoms — difficulty reading, scotomas, dark adaptation problems
- Patients planning long-term subcutaneous PPS — baseline screening before repeated courses
- Patients with pre-existing macular disease — higher vulnerability to additional retinal insult
Screening Protocol
| Timing | Tests |
|---|---|
| Baseline (before or early in PPS use) | OCT, fundus autofluorescence, visual acuity, Amsler grid |
| Annual (for ongoing PPS users) | OCT, fundus autofluorescence |
| If symptoms develop | Urgent: OCT, FAF, NIR, fluorescein angiography, visual field testing |
What to Do If Screening Is Abnormal
Subclinical findings (imaging abnormalities without symptoms):
- Discuss discontinuation of PPS with the prescribing physician
- Weigh the benefit of PPS for the underlying condition against the risk of progressive retinal damage
- Consider alternative treatments for IC (amitriptyline, hydroxyzine, pelvic floor therapy, intravesical instillations)
- Repeat imaging in 3-6 months to assess progression rate
Symptomatic maculopathy:
- Discontinue PPS immediately
- Referral to retina specialist
- Ongoing monitoring (every 3-6 months) because progression can continue post-discontinuation
- Low-vision rehabilitation referral if visual function is significantly affected
- Document cumulative PPS exposure for the ophthalmological record
The Broader Lesson
PPS maculopathy illustrates a principle that is relevant far beyond this single drug: post-market surveillance is imperfect, and long-latency adverse effects can remain undetected for decades. PPS was prescribed to hundreds of thousands of patients for over 20 years before the retinal toxicity was identified.
This has implications for how we think about all long-term medications and therapies:
- Absence of evidence is not evidence of absence. The fact that a side effect has not been reported does not mean it does not exist — it may simply not have been looked for.
- Novel therapeutic mechanisms warrant long-term vigilance. PPS is a semi-synthetic glycosaminoglycan with complex biological activity. Its mechanism of retinal toxicity is still not fully understood.
- Screening saves vision. The patients who benefit most from the identification of PPS maculopathy are those in whom subclinical changes are detected early, allowing discontinuation before irreversible vision loss occurs.
What I Tell My Patients
For my patients using subcutaneous PPS for osteoarthritis, my approach is:
- Baseline eye exam with OCT and FAF before starting the first course. This establishes a reference point.
- Annual retinal screening for patients who plan repeated courses (2+ courses per year).
- Immediate evaluation for any visual changes — however subtle. Do not wait for the annual screening if symptoms develop.
- Honest risk communication. The risk from short-course subcutaneous PPS is substantially lower than from years of oral PPS for IC, but it is not zero, and we do not have long-term data from the OA population.
- Documentation. I track cumulative PPS exposure in the patient’s record so that any future ophthalmologist has the complete picture.
For patients who are currently taking oral PPS for interstitial cystitis and have not had retinal screening, I strongly recommend scheduling an evaluation. If you have been on oral PPS for more than 3 years without an eye exam, this should be a priority.
The Bottom Line
Pentosan polysulfate maculopathy is a real, dose-dependent, progressive, and currently irreversible retinal toxicity that was hidden for over two decades after PPS was approved. It primarily affects long-term oral PPS users (IC patients), with subclinical retinal changes present in approximately 16-24% of those with cumulative exposure exceeding 500 grams. The risk from short-course subcutaneous PPS for osteoarthritis is substantially lower but not negligible for patients planning years of repeated courses. Screening with OCT and fundus autofluorescence is the single most important action any PPS user can take. Early detection, before symptoms develop, provides the best opportunity to stop the drug before irreversible vision loss occurs. If you use PPS for any reason, get your eyes checked.
Back to Pentosan Polysulfate Overview | All Peptide Articles
References
- Pearce WA, Chen R, Jain N. “Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium.” Ophthalmology. 2018;125(11):1793-1802. DOI: 10.1016/j.ophtha.2018.04.026.
- Jain N, Li AL, Yu Y, VanderBeek BL. “Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort.” Br J Ophthalmol. 2020;104(8):1093-1097. DOI: 10.1136/bjophthalmol-2019-314765.
- Hanif AM, Armenti ST, Taylor SC, et al. “Phenotypic spectrum of pentosan polysulfate sodium-associated maculopathy: a multicenter study.” JAMA Ophthalmol. 2019;137(11):1275-1282. DOI: 10.1001/jamaophthalmol.2019.3392.
- U.S. Food and Drug Administration. “FDA Drug Safety Communication: FDA Adds Warnings about Risk of Eye Damage to Prescribing Information for Pentosan Polysulfate Sodium.” June 2020.
- Wang D, Au A, Gunnemann F, et al. “Pentosan polysulfate maculopathy: prevalence, spectrum, and diagnosis with multimodal imaging.” Retina. 2021;41(12):2549-2558.
Disclaimer: This article is provided for educational purposes and reflects one physician’s clinical assessment of published safety data. Pentosan polysulfate maculopathy is a recognized adverse effect documented in the FDA-updated prescribing information. This article is not a recommendation to use or avoid PPS — it is a safety disclosure to support informed decision-making. Consult both your prescribing physician and an ophthalmologist if you use PPS for any indication.
